Daniele Fanale, PhD, University of Palermo, Italy
Dr/Prof Daniele Fanale, PhD, Researcher in Medical Oncology, Biologist Executive at the “Sicilian Regional Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of the Section of Medical Oncology of University Hospital Policlinico “P. Giaccone” of Palermo (Italy). PhD in “Molecular and Cellular Oncopathology” at the University of Palermo (Italy) in 2010. In these years, he has been involved in projects of translational oncology research aimed at identifying new potential biomarkers in cancer for diagnostic, prognostic and predictive purposes. In this context, he has been concerned with the genetic counselling and molecular genetics of sporadic and heredo-familial tumors. For the past year, he has also been involved in the projects concerning the immuno-oncology in several solid tumors.
Mev Domínguez Valentin, PhD, Oslo University Hospital, Norway
Mev Domínguez-Valentin (MDV), PhD is a Project Group Leader in the Department of Tumor Biology of the Institute for Cancer Research from Oslo University Hospital (Norway). She is the Principal Investigator of the largest database in Lynch Syndrome (PLSD) that aims to facilitate personalized precision medicine for Lynch Syndrome.
MDV has had extensive mobility throughout her career, with activity across many countries, and even two continents. Her main research areas include Lynch Syndrome (LS) and the large prospective observational studies that have recently increased understanding of the effectiveness of colonoscopic surveillance and the heterogeneity of cancer risk between genotypes. Also, the use of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing, to gain information on to which degree other genes may have been causative for cancer in the patients and their relatives, and to be informed on how such genes were deranged to discriminate between normal and disease-causing variants. MDV is also interested in unravelling the challenges of implementing the advances in diagnosis of hereditary cancer susceptibility and applying these insights to clinical practice in Latin America. In addition, MDV has established national and international collaborations in LS that have been crucial, especially in generating knowledge about mismatch repair genes variant classification and sharing of genetic practices within the region. MDV pursues her interest in the genetic epidemiology of hereditary cancers in low-resource setting in Peru. At educational and mentoring level, MDV is co-founder of the Research Experience for Peruvian Undergraduates Program (REPU), active mentor of the international mentoring program in Peru and actively promotes the research of Peruvian scientists in Europe (SINAPSIS).
MDV is board member of the European Hereditary Tumor Group (EHTG), Ambassador at the North American Group (CGA) and Scientific advisor of the Latin America Group of the Hereditary Tumors (LA-GETH).
Ling Zhang, MD, H Lee Moffitt Cancer Center and Research Institution, USA
Dr Ling Zhang has engaged in diagnosis and research of cancers, especially hematologic malignancies for the past two decades and would like to share her personal experiences in the application of molecular markers in diagnosis of disease, prediction of disease prognosis, and potential treatment to try to guide authors to contribute advanced research results and reviews in the Collection for best clinical practice and patience care.
